The AP4S1 Knockout A-549 Polyclonal Cells product consists of a heterogeneous population of human A-549 lung epithelial cells genetically modified by CRISPR/Cas9 to disrupt the AP4S1 gene, encoding the sigma4 subunit of the adaptor protein complex 4 (AP-4). This polyclonal format introduces diverse loss-of-function mutations, providing a robust model system for functional studies of AP-4-mediated trafficking while avoiding the selection biases of single-cell clones.
The A-549 cell line was established from a lung adenocarcinoma of a 58-year-old male and is a well-characterized model of type II alveolar epithelial cells. These cells maintain features such as surfactant production and cytokine secretion, and are extensively used in pulmonary biology, cancer research, and intracellular trafficking studies, offering a physiologically relevant background for investigating vesicular transport pathways.
AP4S1 is an essential subunit of the heterotetrameric AP-4 complex, which interacts with the adaptor subunits AP4B1, AP4E1, AP4M1, and the scaffold clathrin to mediate selective cargo sorting from the trans-Golgi network to endosomes and lysosomes. The complex is regulated by the mTORC1 kinase and transcriptionally controlled by TFEB. Key cargoes include ATG9A, a multipass transmembrane protein required for autophagosome formation, and LAMP2, a lysosomal membrane protein. Disruption of AP4S1 abolishes complex assembly, impairing ATG9A trafficking to endosomes and thereby attenuating autophagy flux and lysosomal degradation; this results in accumulation of autophagic substrates and lysosomal dysfunction.
In the A-549 lung cancer background, AP4S1 knockout provides a unique tool to dissect the interplay between AP-4-dependent trafficking, autophagy, and tumor cell biology. Since autophagy can exert context-dependent tumor-suppressive or pro-survival effects, this model enables investigation of how endolysosomal dysfunction influences cancer cell proliferation, metabolic adaptation, and sensitivity to chemotherapeutics. Furthermore, it serves as a surrogate system for studying AP-4 deficiency syndrome and neurodevelopmental disorders such as hereditary spastic paraplegia, as the core trafficking machinery is conserved across cell types, allowing characterization of fundamental pathogenic mechanisms.
Researchers can deploy these polyclonal knockout cells in a wide range of experimental workflows: western blot analysis to confirm AP4S1 loss and monitor downstream effectors, immunofluorescence microscopy to visualize ATG9A mislocalization, autophagy flux assessments using LC3 turnover or p62 clearance, lysosomal cathepsin activity assays, RT-qPCR quantification of TFEB target genes, and flow cytometry for surface or intracellular cargo receptors. Specific applications include mechanistic dissection of AP-4?Cmediated sorting pathways, high-content screening for small molecules that restore trafficking, and translational research on autophagy-related pathologies. For additional technical information and order inquiries, please contact Ascent Research.
